ImmunoBiochem's Angel Round

ImmunoBiochem raised a round of funding on December 11, 2017.

ImmunoBiochem has created a technology that enables the development of antibody drug conjugates (ADCs) targeted at intracellular tumor antigens. ADCs comprise a class of potentiated biological therape…

Articles about ImmunoBiochem's Angel Round: